Crispr Therapeutics AG vs Pinterest Inc — how do they compare? Crispr Therapeutics AG trades at $53.67 (market cap $4.88B), while Pinterest Inc trades at $21.4 (market cap $11.63B). The key difference: Pinterest Inc is far larger — about 2.4× Crispr Therapeutics AG's market cap, and Pinterest Inc is more actively traded (12,792,940 versus 2,861,747). Which is the better fit depends on your goals — on Pluang, investors hold Crispr Therapeutics AG for 77 Days and Pinterest Inc for 85 Days on average.
| CRSP | PINS | |
|---|---|---|
Market Cap | $4.88B | $11.63B |
Volume | 2,861,747 | 12,792,940 |
Sector | Health | Media |
52-Week High | $74.92 | $35.24 |
52-Week Low | $44.34 | $15.42 |
Typical Hold Time | 77 Days | 85 Days |
Enterprise Value | $3.30B | $11.55B |
Signals from Pluang's Aura AI — not financial advice
CRISPR Therapeutics (CRSP) trades at $53.41, up 2.02% with a bearish technical signal despite recent earnings beats. The company shows negative profitability metrics with -$581.60M net income in 2025 and revenue volatility, though analyst consensus remains bullish with a $67.83 price target. Key catalysts include upcoming clinical data presentations for autoimmune disease therapies and CASGEVY commercialization progress.
The stock presents high-risk, high-reward potential with strong Wall Street support (57.9% buy ratings) but faces significant execution risks. Near-term performance hinges on clinical trial outcomes and revenue generation from approved therapies, while persistent cash burn and competitive pressures remain key concerns for investors.
Pinterest (PINS) trades at $21.35, up 5.1% today, showing strong momentum after three consecutive earnings beats. The stock maintains a bullish technical outlook with positive moving averages, though RSI levels suggest potential overbought conditions. Fundamentally, revenue growth accelerated to $4.22 billion in 2025 with improving profitability, though valuation multiples remain elevated with a P/E of 60.4. Recent news highlights the company's visual search ad innovations and international monetization progress.
The outlook remains positive with 54% analyst buy ratings and a $27.93 consensus price target representing 31% upside. Key opportunities include continued international ARPU growth and AI-driven advertising enhancements. Risks include competitive pressure from larger platforms, potential advertising slowdowns, and insider selling activity that may signal caution among company leadership.
Trailing returns across standard periods
What Pluang investors did over the last 30 days
Latest headlines on both assets
CRISPR Therapeutics is a gene editing company focused on the development of CRISPR/Cas9-based therapeutics. CRISPR/Cas9 stands for Clustered Regularly Interspaced Short Palindromic Repeats (CRISPR)/CRISPR-associated protein 9 (Cas9), which is a revolutionary technology for precisely altering specific sequences of genomic DNA. The company is focused on using this technology to treat genetically defined diseases. CRISPR's most advanced pipeline candidate, CTX001, is in collaboration with Vertex Pharmaceuticals and targets sickle cell disease and transfusion-dependent beta-thalassemia, which have high unmet medical needs. The company is progressing additional gene editing programs for immuno-oncology, as well as a stem cell-derived therapy for the treatment of Type 1 diabetes.
Read more on CRSP →Pinterest is an online product and idea discovery platform that helps users gather ideas on everything from recipes to cook to destinations to travel to. Founded in 2010, the platform consists of a largely female audience, at roughly two thirds of its more than 365 million monthly active users. The company generates revenue by selling digital ads and is now rolling out more in-platform e-commerce features.
Read more on PINS →